Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 2:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 21,205 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immunity Disorders Clear all
Completed Phase 1 Interventional

A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Immunotherapeutic P3C541b in HIV-1 Seropositive Human Subjects

NCT00002353
View directory record Official record
Conditions
HIV Infections
Interventions
P3C541b Lipopeptide
Biological
Lead sponsor
United Biomedical
Industry
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 25, 2026, 2:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

eTest: Real-time, Remote Monitoring System for Home-based HIV Testing Among High-risk Men Who Have Sex With Men

NCT03654690
View directory record Official record
Conditions
HIV Infections
Interventions
HIV self-test, Counseling
Diagnostic Test · Behavioral
Lead sponsor
Brown University
Other
Eligibility
18 Years and older · Male only
Enrollment
811 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Oct 25, 2026, 2:05 AM EDT
Completed No phase listed Observational

Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile

NCT01454297
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Not listed
Lead sponsor
Multiple Myeloma Research Foundation
Other
Eligibility
18 Years and older
Enrollment
1,154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
55
States / cities
Scottsdale, Arizona • San Diego, California • San Francisco, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2024 · Synced Oct 25, 2026, 2:05 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Autologous Dendritic Cell Vaccine in HIV1 Infection

NCT00510497
View directory record Official record
Conditions
HIV Infections
Interventions
Autologous HIV-1 ApB DC Vaccine
Biological
Lead sponsor
Sharon Riddler
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 25, 2026, 2:05 AM EDT
Terminated Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

NCT05219513
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
RO7443904, Glofitamab, Obinutuzumab, Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
New York, New York • Cleveland, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 23, 2024 · Synced Oct 25, 2026, 2:05 AM EDT
Not listed No phase listed Observational

Polyomic Biomarker Verification in Adult Chronic Graft-Versus-Host Disease (ABLE3.0/CTTC2201)

NCT05692713
View directory record Official record
Conditions
Chronic Graft-versus-Host-Disease, Allogeneic Hematopoietic Stem Cell Transplantation, Leukemia, Blood Cancer, Non-Malignant Hematologic and Lymphocytic Disorder
Interventions
Not listed
Lead sponsor
University of British Columbia
Other
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
St Louis, Missouri • Omaha, Nebraska • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 8, 2023 · Synced Oct 25, 2026, 2:05 AM EDT
Completed Early Phase 1 Interventional

Injection Of AJCC Stage IIB, IIC, III And IV Melanoma Patients With A Multi-Epitope Peptide Vaccine Using GM-CSF DNA As An Adjuvant: A Pilot Trial To Assess Safety And Immunity

NCT00580060
View directory record Official record
Conditions
Melanoma
Interventions
GM-CSF DNA, NSC 683472 gp100: 209-217(210M), NSC 699048 Tyrosinase: 368-376(370D)
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2011 · Synced Oct 25, 2026, 2:05 AM EDT
Completed Phase 2 Interventional

Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma

NCT00278382
View directory record Official record
Conditions
Anaplastic Large Cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma
Interventions
sorafenib tosylate, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Oct 25, 2026, 2:05 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pregnancy Registry, Infants, Serum/Milk Analysis (PRISMA)

NCT06940323
View directory record Official record
Conditions
Multiple Sclerosis, Clinically Isolated Syndrome, NMOSD, Myasthenia Gravis
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2035
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 25, 2026, 2:05 AM EDT
Completed No phase listed Observational

Utilizing MRI for Earlier Diagnosis of Rheumatoid Arthritis

NCT03841279
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
MRI
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 25, 2026, 2:05 AM EDT
Completed Phase 1 Interventional

Safety of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy

NCT01170286
View directory record Official record
Conditions
Peanut Allergy
Interventions
Whole peanut extract, Placebo formulation
Biological
Lead sponsor
DBV Technologies
Industry
Eligibility
6 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
Little Rock, Arkansas • Denver, Colorado • Willingboro, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2012 · Synced Oct 25, 2026, 2:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Mechanism of Action of Ocrelizumab in Multiple Sclerosis

NCT03344094
View directory record Official record
Conditions
Multiple Sclerosis, Immune System Diseases
Interventions
ocrelizumab
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 21, 2025 · Synced Oct 25, 2026, 2:05 AM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Determine the Immunogenicity and Oral Tolerance to Keyhole Limpet Hemocyanin (KLH)

NCT01489956
View directory record Official record
Conditions
Autoimmune Disorders
Interventions
Immucothel Alone (Part A), Immucothel+Montanide (Part A), Immucothel Alone or Immucothel+Montanide (Part B)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2016 · Synced Oct 25, 2026, 2:05 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

NCT05092451
View directory record Official record
Conditions
B-Cell Lymphoma, Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML), Multiple Myeloma, Plasma Cell Leukemia, Hodgkin Lymphoma, T-cell Non-Hodgkin's Lymphoma/ T-cell Acute Lymphoblastic Leukmeia, Myelodysplastic Syndrome / Chronic Myelomonocytic Leukemia, Blastic Transformation of Chronic Myeloid Leukemia, Germ Cell Tumors
Interventions
Cyclophosphamide, CAR.70/IL15-transduced CB-NK cells, Fludarabine phosphate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 25, 2026, 2:05 AM EDT
Active, not recruiting Phase 4 Interventional

A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)

NCT06101095
View directory record Official record
Conditions
Eosinophilic Oesophagitis
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
15
States / cities
Murrieta, California • San Francisco, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 25, 2026, 2:05 AM EDT
Completed Not applicable Interventional Results available

Women Empowered to Live With Lupus Study

NCT02988661
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Chronic Disease Self-management Program (CDSMP)
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Female only
Enrollment
699 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 25, 2026, 2:05 AM EDT
Recruiting Not applicable Interventional

SMART@Home Feasibility Trial

NCT06159127
View directory record Official record
Conditions
Asthma, Asthma in Children
Interventions
SMART@Home
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years to 18 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 25, 2026, 2:05 AM EDT
Completed No phase listed Observational

A Prospective, Observational Study of Pregnancy Outcomes Among Women Exposed to Truvada for PrEP Indication

NCT01865786
View directory record Official record
Conditions
HIV Infection
Interventions
Not listed
Lead sponsor
Gilead Sciences
Industry
Eligibility
Female only
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 30, 2018 · Synced Oct 25, 2026, 2:05 AM EDT
Completed Phase 3 Interventional Results available

A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis

NCT01194570
View directory record Official record
Conditions
Multiple Sclerosis, Primary Progressive
Interventions
Ocrelizumab, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
735 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
37
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Phoenix, Arkansas + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Oct 25, 2026, 2:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Tralokinumab When Delivered Subcutaneously at Different Flow Rates to Healthy Volunteers

NCT02085473
View directory record Official record
Conditions
Asthma, Healthy Subjects or Volunteers
Interventions
Tralokinumab 300 mg
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
19 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 31, 2018 · Synced Oct 25, 2026, 2:05 AM EDT
Completed Phase 4 Interventional Results available

Crossover Study Comparing Fluticasone Furoate (FF)/Vilanterol (VI) Once Daily Versus Fluticasone Propionate (FP) Twice Daily in Subjects With Asthma and Exercise-Induced Bronchoconstriction (EIB)

NCT02730351
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone furoate/ Vilanterol 100 mcg/25 mcg, Fluticasone propionate 250 mcg, Placebo via ELLIPTA inhaler, Placebo via DISKUS / ACCUHALER
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 50 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
13
States / cities
Huntington Beach, California • Los Angeles, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Oct 25, 2026, 2:05 AM EDT
Completed Phase 2 Interventional

A Study of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and A Second Controller Medication (VERSE)

NCT01545453
View directory record Official record
Conditions
Asthma
Interventions
lebrikizumab, placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
62
States / cities
Oxford, Alabama • Long Beach, California • Los Angeles, California + 57 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 25, 2026, 2:05 AM EDT
Terminated Phase 1 Interventional

A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)

NCT04790903
View directory record Official record
Conditions
Lymphoma, Large B-Cell, Diffuse
Interventions
Venetoclax, Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Oct 25, 2026, 2:05 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma

NCT00742027
View directory record Official record
Conditions
Classical Hodgkin's Lymphoma
Interventions
Panobinostat
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
13
States / cities
Duarte, California • Atlanta, Georgia • Augusta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Oct 25, 2026, 2:05 AM EDT